TY - JOUR
T1 - The hypouricemic effect of Balanophora laxiflora extracts and derived phytochemicals in hyperuricemic mice
AU - Ho, Shang Tse
AU - Tung, Yu Tang
AU - Huang, Chi Chang
AU - Kuo, Chao Lin
AU - Lin, Chi Chen
AU - Yang, Suh Ching
AU - Wu, Jyh Horng
PY - 2012
Y1 - 2012
N2 - The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.
AB - The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.
UR - https://www.scopus.com/pages/publications/84863686319
UR - https://www.scopus.com/pages/publications/84863686319#tab=citedBy
U2 - 10.1155/2012/910152
DO - 10.1155/2012/910152
M3 - Article
C2 - 22778779
AN - SCOPUS:84863686319
SN - 1741-427X
VL - 2012
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
M1 - 910152
ER -